Quantumzyme, a biotransformation company, focused on clean and green chemistry  has recently been granted a patent for the transaminase enzyme by applying its revolutionary technology QZyme WorkbenchTM in India. The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions, which can be useful for pharmaceutical and agricultural industries.

The groundbreaking “QZyme WorkbenchTM" technology can handle a wide range of important aspects of protein modeling and engineering, including structural refinement, ligand docking, conformational sampling, estimating substrate binding affinity, modeling catalytic reactions, identifying mutable hotspots, and further hotspot optimization.

With diabetes quickly becoming a lifestyle disease in India, with over 74 million active patients and a big community that remains undiagnosed. The introduction of more affordable drugs is expected to increase volumes due to improved accessibility. Sitagliptin (Januvia) had its last days in India in the year 2022 and while Sitagliptin is a newer molecule to the Indian market, the cost of therapy is anticipated to fall from Rs. 45 per day charged by Merck to Rs. 8-18 per day charged by generic competitors.

Naveen Kulkarni, CEO, Quantumzyme reports, “Given the current patent and trademark landscape, this is crucial and encouraging for our company. We only hope to create more resourceful green catalysts and develop better technologies to justify our work as a company to provide more efficiently to the industries in need.”

Quantumzyme discovered and optimized a new biocatalytic synthetic route for enantiopure chiral amine, a critical intermediate in the synthesis of Sitagliptin.